(3,3-DIMETHYLOXETAN-2-YL)METHANAMINE, 95.0%, 250mg

Ethyl 2-chloro-5-methylthiazole-4-carboxylate, 95.0%, 1g

(S)-tert-Butyl 2-methylpyrrolidine-1-carboxylate, 95.0%, 25g

tert-Butyl 7-(benzyloxy)-[1,2,4]triazolo[1,5-a]pyridine-8-carboxylate, 98%, 1g

N-(2-(2-(2-(2-(4-(6-Methyl-1,2,4,5-tetrazin-3-yl)phenoxy)ethoxy)ethoxy)ethoxy)ethyl)-5-((3aR,4R,6aS)-2-oxohexahydro-1H-thieno[3,4-d]imidazol-4-yl)pentanamide, 95%, 5mg

p-Toluic acid, 98%, for synthesis, 2.5 kg, plastic packaging.

5-(4,4,5,5-Tetramethyl-1,3,2-dioxaborolan-2-yl)-2,2'-bithiophene>98.0%(GC)25g

tert-Butyl ((3S,4S)-7-cyano-4-methyl-2-oxo-2,3,4,5-tetrahydro-1H-benzo[b][1,4]diazepin-3-yl)carbamate, 98%, 1g

Methyl 2-amino-5-(morpholin-4-yl)benzoate, 98%, 2.5g

Methyl 6-bromoimidazo[1,2-a]pyridine-2-carboxylate, 98.0%, 5g

(2-(Benzyloxy)-4-bromo-6-fluorophenyl)boronic acid, 95.0%, 250mg

N-(4-Bromophenyl)-9,9-dimethyl-9H-fluoren-2-amine>95.0%(HPLC)(N)1g

(R)-3-(1-Aminoethyl)aniline dihydrochloride, 95%, 250mg